545 related articles for article (PubMed ID: 31703649)
21. Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: a single-institution experience.
Gupta T; Agarwal JP; Ghosh-Laskar S; Parikh PM; D'Cruz AK; Dinshaw KA
Head Neck Oncol; 2009 Jun; 1():17. PubMed ID: 19527507
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck.
Day D; Prawira A; Spreafico A; Waldron J; Karithanam R; Giuliani M; Weinreb I; Kim J; Cho J; Hope A; Bayley A; Ringash J; Bratman SV; Jang R; O'Sullivan B; Siu LL; Hansen AR
Oral Oncol; 2020 Sep; 108():104753. PubMed ID: 32464516
[TBL] [Abstract][Full Text] [Related]
23. Retrospective analysis of the incidence and severity of acute kidney injury (AKI) in patients with head and neck cancer receiving weekly cisplatin with radiotherapy (RAISe-AKI).
Dierckes SJ; Ragsdale ME; Macik MR; Weddle KJ
J Oncol Pharm Pract; 2021 Dec; 27(8):1923-1928. PubMed ID: 33302822
[TBL] [Abstract][Full Text] [Related]
24. Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.
Tao Y; Sun XS; Pointreau Y; Le Tourneau C; Sire C; Kaminsky MC; Coutte A; Alfonsi M; Calderon B; Boisselier P; Martin L; Miroir J; Ramee JF; Delord JP; Clatot F; Rolland F; Villa J; Magne N; Elicin O; Gherga E; Nguyen F; Lafond C; Bera G; Calugaru V; Geoffrois L; Chauffert B; Damstrup L; Crompton P; Ennaji A; Gollmer K; Nauwelaerts H; Bourhis J
Eur J Cancer; 2023 Apr; 183():24-37. PubMed ID: 36796234
[TBL] [Abstract][Full Text] [Related]
25. A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma.
Teknos TN; Grecula J; Agrawal A; Old MO; Ozer E; Carrau R; Kang S; Rocco J; Blakaj D; Diavolitsis V; Kumar B; Kumar P; Pan Q; Palettas M; Wei L; Baiocchi R; Savvides P
Invest New Drugs; 2019 Aug; 37(4):702-710. PubMed ID: 30569244
[TBL] [Abstract][Full Text] [Related]
26. Definitive chemoradiotherapy with carboplatin for squamous cell carcinoma of the head and neck.
Nagasaka M; Zaki M; Issa M; Kim H; Abrams J; Sukari A
Laryngoscope; 2017 Oct; 127(10):2260-2264. PubMed ID: 28271529
[TBL] [Abstract][Full Text] [Related]
27. Increased acute mortality with chemoradiotherapy for locally advanced head and neck cancer in patients ≥70years.
Strom TJ; Naghavi AO; Trotti AM; Russell J; Kish JA; McCaffrey J; Otto KJ; Harrison LB; Caudell JJ
J Geriatr Oncol; 2017 Jan; 8(1):50-55. PubMed ID: 27720129
[TBL] [Abstract][Full Text] [Related]
28. Angiotensin-converting enzyme inhibitors predict acute kidney injury during chemoradiation for head and neck cancer.
Spiotto MT; Cao H; Mell L; Toback FG
Anticancer Drugs; 2015 Mar; 26(3):343-9. PubMed ID: 25486599
[TBL] [Abstract][Full Text] [Related]
29. High-dose or low-dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer.
Chang CL; Yuan KS; Wu SY
Head Neck; 2017 Jul; 39(7):1364-1370. PubMed ID: 28370614
[TBL] [Abstract][Full Text] [Related]
30. Comparison of standard-dose 3-weekly cisplatin and low-dose weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer: A multicenter retrospective analysis.
Lee SY; Choi YS; Song IC; Park SG; Keam B; Yang YJ; Song EK; Lee HJ; Cho SH; Shim H; Park KU; Lee KH; Jo DY; Jo IS; Yun HJ;
Medicine (Baltimore); 2018 May; 97(21):e10778. PubMed ID: 29794758
[TBL] [Abstract][Full Text] [Related]
31. Concurrent weekly cisplatin and simultaneous integrated boost intensity-modulated radiotherapy of locally advanced squamous cell carcinoma of the head and neck.
Dubinský P; Jeremic B; Švajdová M; Barilíková G; Matula P; Nadzonová D; Vojtek V
Klin Onkol; 2022; 35(4):307-314. PubMed ID: 35989088
[TBL] [Abstract][Full Text] [Related]
32. A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN).
Camille N; Rozehnal J; Roy E; Uczkowski D; Olson A; Genden E; Teng M; Bakst R; Gupta V; Posner M; Misiukiewicz K
Oral Oncol; 2017 Aug; 71():99-104. PubMed ID: 28688700
[TBL] [Abstract][Full Text] [Related]
33. Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer.
Melotek JM; Cooper BT; Koshy M; Silverman JS; Spiotto MT
J Otolaryngol Head Neck Surg; 2016 Nov; 45(1):62. PubMed ID: 27881143
[TBL] [Abstract][Full Text] [Related]
34. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.
Spreafico A; Huang SH; Xu W; Granata R; Liu CS; Waldron JN; Chen E; Ringash J; Bayley A; Chan KK; Hope AJ; Cho J; Razak AA; Hansen A; Jang R; Perez-Ordonez B; Weinreb I; Bossi P; Orlandi E; Licitra LF; Song Y; O'Sullivan B; Siu LL; Kim J
Eur J Cancer; 2016 Nov; 67():174-182. PubMed ID: 27669504
[TBL] [Abstract][Full Text] [Related]
35. Concurrent Chemoradiation with Weekly Cisplatin for the Treatment of Head and Neck Cancers: an Institutional Study on Acute Toxicity and Response to Treatment.
Ghosh S; Rao PB; Kumar PR; Manam S
Asian Pac J Cancer Prev; 2015; 16(16):7331-5. PubMed ID: 26514533
[TBL] [Abstract][Full Text] [Related]
36. IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck.
Montejo ME; Shrieve DC; Bentz BG; Hunt JP; Buchman LO; Agarwal N; Hitchcock YJ
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e845-52. PubMed ID: 21167654
[TBL] [Abstract][Full Text] [Related]
37. Comparing high-dose cisplatin with cisplatin-based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC).
Furqan M; Snyders TP; Saqlain MU; Mott SL; Laux D; Snow A; Anderson CM; Watkins JM; Clamon GH
Cancer Med; 2019 Jun; 8(6):2730-2739. PubMed ID: 30968604
[TBL] [Abstract][Full Text] [Related]
38. Comparison of acute toxicities in two primary chemoradiation regimens in the treatment of advanced head and neck squamous cell carcinoma.
Fan KY; Gogineni H; Zaboli D; Lake S; Zahurak ML; Best SR; Levine MA; Tang M; Zinreich ES; Saunders JR; Califano JA; Blanco RG; Pai SI; Messing B; Ha PK
Ann Surg Oncol; 2012 Jun; 19(6):1980-7. PubMed ID: 22290566
[TBL] [Abstract][Full Text] [Related]
39. Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Le Tourneau C; Tao Y; Gomez-Roca C; Cristina V; Borcoman E; Deutsch E; Bahleda R; Calugaru V; Modesto A; Rouits E; Gollmer K; Vuagniaux G; Crompton P; Zanna C; Szyldergemajn S; Delord JP; Bourhis J
Clin Cancer Res; 2020 Dec; 26(24):6429-6436. PubMed ID: 32994295
[TBL] [Abstract][Full Text] [Related]
40. A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck.
Varveris H; Mazonakis M; Vlachaki M; Kachris S; Lyraraki E; Zoras O; Maris T; Froudarakis M; Velegrakis J; Perysinakis C; Damilakis J; Samonis G
Oncol Rep; 2003; 10(1):185-95. PubMed ID: 12469168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
